凯德诊断 CDNA

Mr. John Walter Hanna, Jr serves as Director, President and Chief Executive Officer at company. Professional experience includes President and Chief Executive Officer, CareDx, Inc. (2024 - present); Vice President, Corporate Development, Pacific Biosciences of California, Inc. (2023 - 2024); Chief Executive Officer, Apton Biosystem, Inc. (2021 - 2023); and Chief Commercial Officer, Veracyte, Inc. (2011 - 2021). Current organization affiliation includes CareDx, Inc. Previous organizations include Pacific Biosciences of California, Inc., Apton Biosystem, Inc., and Veracyte, Inc. Education includes a Master of Business Administration degree from the University of Miami and a Bachelor of Science degree in Political Science from Hampden Sydney College.

Keith Kennedy has served as our Chief Operating Officer since September 2024. Prior to joining us, Mr Kennedy served as the Chief Financial Officer of PharmaLogic Holdings Corp from April 2022 to September 2024. Mr. Kennedy served as Veractye, Inc.'s Chief Operating Officer from July 2019, as well as its Chief Financial Officer from December 2016, until his retirement in May 2021, as well as its Secretary from November 2017 to July 2020. Prior to joining Veracyte, Mr. Kennedy provided strategic counsel and consulting services from his consulting practice from September 2015 to November 2016, including advisory services to Pennant Park Investment Advisors. Mr. Kennedy served as President, Chief Executive Officer and Director of MCG Capital Corporation, a publicly traded business development company, from April 2014 until its merger with Pennant Park Floating Rate Capital Ltd in August 2015. Mr. Kennedy joined MCG Capital Corporation in February 2012 as an Executive Vice President and Managing Director, served as its Chief Financial Officer and Treasurer from May 2012 to March 2014, and its President from March to April 2014. Prior to MCG, Mr. Kennedy served as a Managing Director at GE Capital, a Manager of Transaction Services at Ernst & Young LLP and as an Officer in the U.S. Air Force. Mr. Kennedy holds a B.S. in Accounting with high distinction from Indiana University and holds an M.B.A. from the College of William & Mary. Mr. Kennedy is a Chartered Financial Analyst and Certified Public Accountant.

Jessica Meng was appointed as our Chief Commercial Officer, effective September 12, 2024. Ms. Meng previously served as Chief Commercial Officer at DELFI Diagnostics from July 2022 to September 2023, where she served first as a consultant beginning January 2022. Ms. Meng served as Chief Commercial Officer and General Manager of Women's Health at Myovant Sciences from May 2020 to December 2021. Ms. Meng previously held roles of increasing responsibility in sales and marketing leadership at Veracyte from November 2017 to May 2020 and Genentech from 2004 to 2017. Prior to Genentech she worked at Progress Software and Monitor Company. Ms. Meng received a Bachelor of Science in Finance and Bachelor of Arts in International Relations with a minor in Mathematics from the University of Pennsylvania, and a Master's in Business Administration, Marketing, Strategic Management from The Wharton School.

Jeffrey Novack joined CareDx in 2021 and has served as our General Counsel since December 2023 and as our Secretary since April 2024. Before joining CareDx, Mr. Novack served as an Assistant Attorney General in the Investor Protection Bureau of the New York Attorney General's Office. Prior to that, Mr. Novack practiced at two international law firms and clerked for The Honorable Renee Marie Bumb, Chief Judge of the United States District Court for the District of New Jersey. Mr. Novack is a graduate of New York University School of Law and Washington University in St. Louis - Olin Business School. Mr. Novack is admitted to practice law in New York and New Jersey.

Mr. Suresh Gunasekaran serves as Independent Director at company. President and Chief Executive Officer, UCSF Health (2022 - present); Chief Executive Officer and Associate Vice President, University of Iowa Hospitals and Clinics (2018 - 2022); Senior Executive Officer, Southwestern Health Resources Population Health Services Company (2017 - 2018); Chief Operating Officer, UT Southwestern Medical Center (2015 - 2018); and Associate Vice President, Health System Affairs and Chief Information Officer, Southwestern Medical Center (2004 - 2014). Current role includes Chief Executive Officer, UCSF Health. Previous organizations include University of Iowa Hospitals and Clinics, Southwestern Health Resources Population Health Services Company, and Southwestern Medical Center. Education includes a Master of Business Administration degree from Southern Methodist University.

Mr. Michael D. Goldberg serves as Chairman of the Board at company. Professional experience includes Partner, Mohr Davidow Ventures (2005 - 2011); Founder and Chief Executive Officer, Axion (1987 - 1995), acquired by Bristol-Myers Squibb (NYSE: BMS); Partner, Sevin Rosen Management Company (1985 - 1987); and Director, Corporate Development, Cetus Corporation (1981 - 1985). Board service includes Executive Chairman and Director, DNAnexus (2013 - present); Chairman, YorLabs (2018 - present); Chairman, iRhythm Technologies (NASDAQ: IRTC) (2007 - 2010); Chairman, Crescendo Biosciences (2007 - 2010), acquired by Myriad Genetics (NASDAQ: MYGN); Director, eHealth (NASDAQ: EHTH) (1999 - 2021); and Director, Genomic Health, acquired by Exact Sciences (NASDAQ: EXAS) (2001 - 2007). Previous affiliations include Founding Board Member, California Institute for Regenerative Medicine; Board Member, Western Association of Venture Capitalists; Advisory Board Member, Harvard Center for Genetics and Genomics; Advisory Board Member, Berkeley Center for Law and Technology; Advisory Board Member, UCSF Center for Translational and Policy Research on Personalized Medicine; Advisory Board Member, Stanford Distinguished Careers Institute; and Trustee, National Childhood Cancer Foundation. Education includes a Master of Business Administration degree from Stanford Graduate School of Business and a Bachelor of Arts degree from Brandeis University.

Dr. Hannah A. Valantine, M.D. serves as Independent Director at company. Professional experience includes Professor of Medicine, Stanford School of Medicine (2000 - present); Chief Officer for Scientific Workforce Diversity, National Institutes of Health (2014 - 2020); Senior Associate Dean for Diversity and Leadership, Stanford School of Medicine (2005 - 2014); Assistant Professor of Medicine, Stanford School of Medicine (1987 - 2000); and Registrar, Hammersmith Hospitals NHS Trust. Board service includes Director, BridgeBio Pharma (NASDAQ: BBIO) (2021 - present), and Director, Pacific Biosciences (NASDAQ: PACB) (2021 - present). Current organizational affiliations include Founder and Principal, HAV; Member, National Academy of Medicine; and Member, Stanford Cardiovascular Institute. Previous affiliations include President (Western State Affiliation), American Heart Association. Education includes a Doctor of Medicine degree from London University, a Fellowship at Stanford University, and a Bachelor of Medicine and Bachelor of Surgery degree from London University.

Mr. Arthur A. Torres serves as Independent Director at company. Professional experience includes Regent Emeritus, University of California Board of Regents; Vice Chair Emeritus, California Institute for Regenerative Medicine; Director, San Francisco Municipal Transportation Agency (2017 - 2020); President and Member, San Francisco Public Utilities Commission (2010 - 2014); Member, Covered California Board of Directors; Chairman, California Democratic Party (1996 - 2009); Senator, California State Senate (1982 - 1994), including Chair of the California Senate Insurance Committee and Chair of the California Senate Toxics Committee; and Assembly Member, California State Assembly (1974 - 1982), including Chair of the California Assembly Health Committee (1978 - 1994). Current organizational involvement includes Member, Board of Directors, Lifeguard Health Networks, and Board Member and Member of the Audit Committee, PFM. Previous organizations and affiliations include Vice Chair Emeritus, California Institute for Regenerative Medicine; Vice Chair Emeritus, One Legacy, an organ transplant foundation; Alumni Regent and President Emeritus, University of California Alumni Association; Alumni Regent Emeritus, University of California; Board Member Emeritus, Covered California; Fellow, German Marshall Fund; JFK Teaching Fellow, Harvard University; and Visiting Professor, University of San Francisco School of Nursing. Educational background includes a Juris Doctor degree from the University of California Davis School of Law and a Bachelor of Arts in Government from the University of California Santa Cruz. He will not standing for re-election at the Annual Meeting.

Dr. Peter Maag, PhD serves as Independent Director at company. Professional experience includes Chief Executive Officer, Kyverna Therapeutics (NASDAQ: KYTX) (2022 - 2024); Executive Chairman, CareDx (NASDAQ: CDNA) (2020 - 2021); Chief Executive Officer and President, CareDx (NASDAQ: CDNA) (2012 - 2020); Division President, Novartis Diagnostics AG (NYSE: NVS) (2009 - 2012); Chief Executive Officer and Country President, Novartis AG, Germany (NYSE: NVS) (2006 - 2008); Chief Executive Officer and Country President, Novartis AG, Korea (2003 - 2005); Head of Division, Franchise Infectious Diseases, Novartis AG (2002 - 2003); Head of Strategy, Pharma Division, Novartis AG (2001 - 2002); and Associate Principal, McKinsey and Company (1994 - 2001). Board service includes Director, Kyverna Therapeutics (2022 - 2024); Director, MiroMatrix Medical (2021 - 2023), which was acquired by United Therapeutics (NASDAQ: UTHR) in December 2023; Director, Phoenix Pharmahandel (2012 - present); Director, MolecularMD (2012 - 2020); Director, Chiron France (2009 - 2012); Director, Novartis AG, Germany (2006 - 2008); Director, Zuellig Pharma (2003 - 2005); and Director, Novartis Korea (2003 - 2005). Current organizational affiliations include Director, Personalized Medicine Coalition, and Director, BluLake Ventures LLC. Education includes a Ph.D. from the University of Berlin and an MSc from the University of Heidelberg and the University of London. He will not standing for re-election at the Annual Meeting.

Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D. serves as Independent Director at company. Professional experience includes Founder and Chairman, Monograph Capital Partners (2021 - present); Founder and Senior Managing Director, Vida Ventures (2017 - present); Senior Advisor and Retired Partner, TPG (2001 - present); and Professor of Cellular and Molecular Pharmacology, University of California, San Francisco (UCSF) (1988 - 2016). Board service includes Director, Kyverna Therapeutics (2020 - present); Director, Progyny (NASDAQ: PGNY) (2019 - 2025); Director, Intellia Therapeutics (NASDAQ: NTLA) (2019 - present); Director, UroGen Pharma (NASDAQ: URGN) (2017 - 2024); Director, Novotech (2017 - present); Director, Tandem Diabetes Care (NASDAQ: TNDM) (2013 - 2019); Director, BioCryst Pharmaceuticals (NASDAQ: BCRX) (2013 - 2019); Director, Five Prime Therapeutics (NASDAQ: FPRX) (2013 - 2018); Director, Veracyte (NASDAQ: VCYT) (2013 - 2019); Director, Roka Biosciences (NASDAQ: ROKA) (2014 - 2017); Director, Quintiles (NYSE: Q), subsequently merged with IQVIA Holdings (2013 - 2015); Director, Genomic Health (NASDAQ: GHDX), acquired by Exact Sciences (2005 - 2019); and Director, Matrix Laboratories (2004 - 2009). Current affiliations include Member, American Academy of Arts and Sciences; Fellow, National Academy of Medicine; and Fellow, American Medical Informatics Association. Previous affiliations include Trustee, Autistica; Fellow, American College of Physicians; Member, Association of American Physicians; Fellow, Western Association of Physicians; and Member, American Society for Clinical Investigation. Education includes a Ph.D. from Oxford University, an M.D. from Stanford University, and a B.S. from Yale University.